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demographics. RESULTS: What single intervention should we
currently use? HPV vaccine (three doses, costing $120 per dose at
age 12) is not cost-effective as its cost per Quality-Adjusted-Life-
Year (QALY) is more than three times the magnitude of the GNP
per head. Adoption of a thrice a lifetime PAP screening strategy
dominates (ie: costs less and adds more QALYs) the current
strategy, which opportunistically gives PAP screens to 12.2% of
females annually. However, because of the inevitable future fall in
the HPV vaccine price, it is not recommended to abandon the
current opportunistic PAP smear strategy for a more systematic
thrice a lifetime strategy. When should the HPV vaccination be
adopted? Assuming non-waning efﬁcacy, HPV vaccinations
become cost effective when cost falls below $97 per dose, become
very cost-effective (ie: cost per QALY < per capita GNP) when
cost falls below $50 per dose and become cost-saving (ie: gains in
decreased treatment costs exceed increased screening, program
and training costs) when cost per dose falls below the $27.20
threshold. After HPV vaccination is adopted, should we still have
screening programs? Expansion of the PAP program to a penta-
annual PAP program would provide the most additional QALYs
within cost-effectiveness constraints. CONCLUSION: PAP com-
pliancy should be increased to 20.0% per annum, both before
and after the vaccination is introduced. An HPV vaccination
program should be adopted when the vaccine price drops to a
level that it becomes affordable to the Ministry of Health or falls
below $20.44 per dose, providing a cost-saving incentive to the
health insurance funds.
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OBJECTIVE: Geﬁtinib, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, is a new treatment option for
non-small cell lung cancer (NSCLC). Some studies have found
better clinical outcomes for geﬁtinib treatment in women, never-
smokers, certain mutation in the tumor EGFR gene, and patients
with adenocarcinoma and in East Asian ethnicity. However,
geﬁtinib is currently regarded as a salvage treatment rather than
a ﬁrst-line option. The objective of this study was to assess the
cost-effectiveness of geﬁtinib for ﬁrst-line treatment of the inop-
erable, chemo-naïve NSCLC patients in Taiwan. METHODS:
We developed a Markov model of the cost, quality of life, sur-
vival, and incremental cost-effectiveness of the alternative option
with geﬁtinib for ﬁrst-line treatment, as compared with current
practice of platinum-based chemotherapy regiments. Variables of
clinical effectiveness were determined from corresponding trials.
The economic analysis adopted the health care payer’s perspec-
tive, and only direct medical costs were taken into account.
RESULTS: Use of geﬁtinib for ﬁrst-line treatment had a better
mean survival than platinum-based chemotherapies (13.1 versus
11.6 months) while increasing lifetime cost. Given the base-case
assumptions, we found that geﬁtinib increased life expectancy by
1.49 months, or 0.80 quality-adjusted months, at an estimated
cost of $4,140 per treated patient, for an incremental cost-
effectiveness ratio (ICER) of $62,100 per quality-adjusted life-
year (QALY). The ICER would decrease to $48,600 per QALY
gained when such analysis was applied to a subgroup of patients
with molecular marker of EGFR exon 19 deletion or L858R
mutations while they had a signiﬁcantly longer mean survival of
20.8 months. Sensitivity analyses showed that this ICER
remained below $100,000 per QALY for all model variables.
CONCLUSION: Use of geﬁtinib for ﬁrst-line treatment has a
cost-effectiveness ratio below $50,000 per QALY gained in
advanced NSCLC patients with preferred clinical characteristics
in which a signiﬁcant extension of overall survival has been
demonstrated.
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OBJECTIVE: Currently imatinib resistant or intolerant CML
patients have minimally effective therapies available. Dasatinib
binds to the protein Bcr-Abl; it binds also to active and inactive
forms of protein, while imatinib binds only to the inactive forms.
Therefore, mutations that affect the active form can lead to
resistance to imatinib. A Markov model was built to evaluate the
long-term cost-effectiveness of dasatinib in the treatment of adult
CML patients, after resistance or intolerance to imatinib.
METHODS: The model consists of an initial within-trial period
in which best response rates observed from the clinical trials
are used. Response was deﬁned as best response of complete
hematologic response (CHR), minor cytogenetic response (CyR),
minimal CyR, partial CyR, and complete CyR. The model simu-
lates patients moving between health states using progression
probabilities derived from the literature and BMS clinical trials.
The time horizon was the lifetime of patients in the cohort,
allowing evaluation of life expectancy and lifetime costs. Brazil-
ian costs and health resource estimates were applied to the treat-
ment of the different phases of CML. RESULTS: For CML
patients in CP dasatinib provided 0.66 QALYs per patient and
the ICER was R$80,000 with an additional life expectancy of
0.98 years. In the case of AP dasatinib provided an additional life
expectancy of 3.48 years with a ICER of R$91,000. And in the
BP dasatinib provided an additional life expectancy of 1.91 years
with a ICER of R$123,000. CONCLUSION: The CE analysis
showed that dasatinib is more cost-effective in the resistant or
intolerant patients than imatinib in the three phases of CML with
increased life expectancy with quality. Though there is an incre-
mental cost associated to the treatment with dasatinib, the cost is
related to longer life expectancy and therefore expenditure of
more resources.
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OBJECTIVE: Gastric cancer is the ﬁfth most prevalent cancer
and the ﬁfth cause of cancer-related mortality in Taiwan. The
objective of this study was to access the cost-effectiveness of
capecitabine plus cisplatin (XP) vs. intravenous 5-ﬂuorouracil
plus cisplatin (FP) for the treatment of advanced and metastatic
gastric cancer (AGC) in Taiwan, from a payer’s (Bureau of
National Health Insurance [BNHI]) perspective. METHODS: A
cost-minimization analysis (CMA) was conducted by applying
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clinical outcomes and medical resource utilization (MRU)
derived from the phase III ML17032 study. Direct medical costs
associated with trial-based MRU were based on Taiwan’s
National Health Insurance fee schedule for 2007. Costs associ-
ated with intravenous chemotherapy administration and adverse
event (AE) management were estimated by an expert panel
survey conducted among 12 oncologists. One-way sensitivity
analyses were performed on key model parameters by varying the
input values by 20%. RESULTS: A trend toward superior
progression-free survival was observed in the XP arm (median
5.6 months for XP vs. 5.0 for FP). Patients in the XP arm received
5.2 cycles of therapy vs. 4.6 cycles of FP. Compared to FP,
administration of XP required fewer consults per patient (5.2
for XP vs. 22.8 for FP). Chemotherapy drug cost was higher
(USD$1712) in the XP arm; however, these cost increments
were offset by differences of chemotherapy administration costs
(USD$4376) between two arms. AE proﬁles were similar and the
cost associated with grade 3/4 AE management were slightly
lower (USD $30) in the XP arm. Overall, XP was associated
with a cost saving of USD$2691(NTD$87,351). XP remained
cost-saving under one-way sensitivity analyses. CONCLUSION:
From the Taiwan BNHI perspective, this CMA demonstrates that
replacing FP by XP for the treatment of AGC would not only
save direct medical costs but also improve health outcomes in
Taiwan.
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OBJECTIVE: To undertake a cost-consequence analysis of
direct medical costs in the treatment of advanced oesophago-
gastric cancer based on the REAL 2 randomized clinical trial,
which demonstrated non-inferiority when oral capecitabine was
substituted for infusional 5FU as part of the standard regimen,
ECF. METHODS: Direct medical costs (2007 CDN$) from the
perspective of the Canadian public health system were applied
to resources (e.g., study treatment, toxicity management)
obtained from REAL 2 trial data available in the public
domain. Complete drug delivery was assumed. Mean overall
costs per patient were estimated over six cycles, corresponding
to treatment duration. RESULTS: The mean total cost per
patient treated with ECF was $9065 and $9268 for ECX. The
major driver of cost in the ECX arm is chemotherapy drug,
$5472 for capecitabine versus $2400 for infusional 5FU (6
cycles). This is offset by the cost of chemotherapy administra-
tion, $1551 for ECF compared to $671 for ECX, and central
venous access costs, $1230 for ECF. Additional line complica-
tion and hospitalization data were not available and therefore
not included in these estimates. Limited data on toxicity man-
agement, (e.g. febrile neutropenia, anemia, thromboembolism),
are available, and cost estimates are $2955 for ECF
and $2433 for ECX-treated patients. CONCLUSION: ECX has
similar efﬁcacy to ECF in the REAL 2 trial, but has potential
advantages in terms of patient preference and convenience of
an oral therapy. In addition, oral therapy decreases hospital
resource consumption. While drug costs for ECX are greater,
costs for chemotherapy administration and line-related costs
are substantially less, and underestimated in this analysis. Sub-
stituting capecitabine for infusional 5FU in the ECF regimen is
an attractive and affordable alternative for patients with
advanced oesophagogastic cancer.
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OBJECTIVE: In Finland, the overall costs of breast cancer man-
agement have increased, primarily during the last years by the
launch of expensive pharmaceutical therapies (trastuzumab in
2000). Economical reasons may therefore play a part in the
prescribing of new drugs. We analyzed with comprehensive time
series of all expenditures the effectiveness of pharmaceutical
developments and other interventions from 1987 to 2005.
METHODS: Finnish registry based data from 1987 to 2005 was
combined to evaluate all costs related to the care of breast cancer.
These included comprehensive health care costs, sick-leave
compensations, disability pensions, and loss of productivity;
all converted to 2004 euros. Several scenarios were thereafter
constructed to identify the important changes in care processes
and cost drivers during this period. RESULTS: During the obser-
vation period, the number of patients with breast cancer (5-year
survival prevalence) increased by 100% up to 17,000 patients
and the overall expenditure of care more than doubled from €70
to €160 million. The health care costs increased by 150% and the
cumulative costs per patient increased from €4500 to €5500. The
cost of medications has escalated with an overall increase of
660%, mostly during 2000’s. However, during this period, the
effectiveness of the treatment has increased as breast cancer
related deaths, in-hospital days and loss of productivity due to
premature deaths have decreased signiﬁcantly. Altogether, our
scenarios showed that new medications have had a beneﬁcial
ﬁnancial impact of 16–35 million € for the society during the
study period. CONCLUSION: Comprehensive assessment of
large patient cohorts and long term economical outcomes is a
useful method for evaluation of outcomes in chronic diseases.
Identiﬁcation of different cost drivers is needed as the cost of new
interventions is increasing and their beneﬁts should ideally be
assessed in relation to their broader societal inﬂuence.
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OBJECTIVE: This study provides updated, in-depth estimates of
colorectal cancer (CRC) treatment costs. METHODS: This ret-
rospective cohort study included patients aged 65 years, who
were recently diagnosed with colon (CC) or rectal (RC) cancer in
a SEER registry between 1996 and 2002 (n = 60,916) and 1:1
matched (by age, sex, geographic region) non-cancer comparison
patients from a 5% Medicare sample. We assigned costs to
phases as follows: 1) initial: costs in the period up to one year
after diagnosis among patients with 13 months survival; 2)
continuing: costs in the years between the initial and terminal
years among patients with36 months survival; and 3) terminal:
costs in the ﬁnal year of life. Terminal costs were assigned ﬁrst
(all costs considered terminal for patients who lived <13
months). Costs reﬂect all provider payments for cancer patients
in excess of those for matched comparison patients (2006 US
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